APIXAVAC 5 MG

APIXAVAC 5 mg contains Apixaban, a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, a key component in the blood clotting cascade. It is primarily prescribed for the prevention and treatment of thromboembolic disorders, such as stroke in patients with non-valvular atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE).

Key Features:

• Effective and predictable anticoagulant action

• Reduces risk of stroke and blood clots in high-risk patients

• No routine INR monitoring required

• Twice-daily oral dosing ensures consistent blood thinning

• Lower risk of major bleeding compared to traditional anticoagulants like warfarin